Comprehensive Effects of Magnesium Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis
Mohammadi S, Palermo A, Ojani P, Alaghemand N, Pirayvatlou PS, Mirkarimi M, Mavi SA, Tahouri K, Shokouhifar S, Ettehad Y, Borzabadi A, Ashtary-Larky D, Suzuki K, Bouzas C, Rodrigues D, Tur JA
Nutrients · 0 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Instituto de Salud Carlos III
- Gobierno
- European Regional Development
- Gobierno
- Ministerio de Ciencias e Innovación, Spain
- Universidad u hospital
- Health Research Institute of the Balearic Islands
- Subvenciones
- Instituto de Salud Carlos III (CIBEROBN CB12/03/30038)
Según 4 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-07-25 · Nutrients · vol. 18 · número 15 · pág. 2435
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 0 citas · más que el 56% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Adipokines, Inflammation, and Metabolic Diseases
- Palabras clave
- Glycated hemoglobin, Blood pressure, Glycemic, Insulin resistance, Lipid profile, Body mass index, Lipoprotein, Homeostatic model assessment, Randomized controlled trial
- MeSH
- humans, magnesium, blood glucose, lipids, risk factors, blood pressure, dose-response relationship, drug, dietary supplements, randomized controlled trials as topic, biomarkers, cardiometabolic risk factors
16 autores
- Shooka Mohammadi🇲🇾University of Malaya
- Andrea Palermo🇮🇹Università Campus Bio-Medico
- Pantea Ojani🇺🇸Boston University
- Navid Alaghemand🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Pouyan Sanjari Pirayvatlou🇺🇸Saint Agnes Medical Center
- Mohammadreza Mirkarimi🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Sara Ayazian Mavi🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Kia Tahouri🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Shokoufeh Shokouhifar🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Yeganeh Ettehad🇮🇷Jahrom University of Medical Sciences
- Aida Borzabadi🇮🇷Jahrom University of Medical Sciences
- Damoon Ashtary‐Larky🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Katsuhiko Suzuki🇯🇵Waseda University
- Cristina Bouzas🇪🇸Universitat de les Illes Balears
- Daniela Christ Rodrigues🇵🇹University of Coimbra
- Josep Antoni Tur🇪🇸 · autor de correspondenciaUniversitat de les Illes Balears
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background: Evidence regarding the impacts of magnesium (Mg) supplementation on cardiometabolic risk factors (CMRFs) remains inconsistent. Objectives: This systematic review and dose-response meta-analysis evaluated effects of Mg supplementation on anthropometric indices, liver and kidney function, lipid and glycemic profiles, blood pressure, and inflammatory biomarkers. Methods: A systematic search of electronic databases up to May 2026 identified 78 eligible randomized controlled trials. Results: Mg supplementation significantly reduced body weight (weighted mean difference [WMD]: -0.70 kg; 95% confidence interval [CI]: -1.30, -0.09), diastolic blood pressure (WMD: -1.58 mmHg; 95% CI: -2.50, -0.65), homeostasis model assessment of insulin resistance (WMD: -0.48; 95% CI: -0.79, -0.18), low-density lipoprotein cholesterol (WMD: -3.21 mg/dL; 95% CI: -5.27, -1.15), fasting blood glucose (WMD: -3.60 mg/dL; 95% CI: -6.13, -1.06), systolic blood pressure (WMD: -2.50 mmHg; 95% CI: -4.08, -0.91), glycated hemoglobin (WMD: -0.15%; 95% CI: -0.26, -0.03), triglycerides (WMD: -9.24 mg/dL; 95% CI: -16.87, -1.61), and interleukin-6 levels (WMD: -1.10 pg/mL; 95% CI: -1.93, -0.27) compared with controls. High-density lipoprotein cholesterol concentrations significantly increased (WMD: 1.45 mg/dL; 95% CI: 0.37, 2.54). No significant effects were identified on hip circumference, alanine aminotransferase, waist circumference, tumor necrosis factor-α, creatinine, C-reactive protein, body mass index, total cholesterol, fasting insulin, body fat percentage, and aspartate aminotransferase. Most RCTs (79.5%) administered Mg doses ≥ 300 mg/day, and 66.7% had intervention durations ≥ 12 weeks; however, evidence from higher-dose (≥500 mg/day) and longer-term (≥25 weeks) interventions remained limited. Conclusions: Mg supplementation was associated with significant improvements in several CMRFs, including body weight, lipid and glycemic profiles, blood pressure, and interleukin-6 levels. However, these effects were generally modest, and their clinical relevance remains uncertain given the variable certainty of evidence across outcomes.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.